Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Abstract:
      Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior understanding of functional epitopes on Pfs230 is based on two monoclonal antibodies (mAbs) with moderate transmission-reducing activity (TRA), elicited from subunit immunization. Here, we screened the B cell repertoire of two naturally exposed individuals possessing serum TRA and identified five potent mAbs from sixteen Pfs230 domain-1-specific mAbs. Structures of three potent and three low-activity antibodies bound to Pfs230 domain 1 revealed four distinct epitopes. Highly potent mAbs from natural infection recognized a common conformational epitope that is highly conserved across P. falciparum field isolates, while antibodies with negligible TRA derived from natural infection or immunization recognized three distinct sites. Our study provides molecular blueprints describing P. falciparum TRA, informed by contrasting potent and non-functional epitopes elicited by natural exposure and vaccination. [Display omitted] • Isolated mAbs directed to Pfs230 elicited in naturally exposed individuals • Highly potent transmission-reducing mAbs identified that target Pfs230 domain 1 • Structural delineation reveals potent and non-functional epitopes on Pfs230 domain 1 Pfs230 domain 1 represents the most clinically advanced transmission-blocking vaccine candidate, but how human antibodies acquired after natural exposure recognize the protein is unknown. Ivanochko et al. report a panel of human mAbs targeting Pfs230 D1, including the most potent mAbs reported to date, and contrast structure-activity relationships against this malarial antigen to reveal the determinants of transmission-reducing activity. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Immunity (10747613) is the property of Cell Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)